MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Lannett Company Operativer Cashflow 2011-2026 | LCI
Operativer Cashflow Jährlich Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.12 M | 60.9 M | 116 M | 176 M | 119 M | 165 M | 135 M | 129 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 176 M | -7.12 M | 112 M |
Operativer Cashflow Vierteljährlich Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -11.3 M | -30.5 M | - | - | 17.2 M | 13.8 M | - | - | -12.2 M | -24.6 M | -12.2 M | - | 4.28 M | 47.7 M | 4.28 M | - | 54.7 M | 94 M | 54.7 M | - | -1.58 M | 76.1 M | -1.58 M | - | 36.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 94 M | -30.5 M | 18.2 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.47 | 4.37 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 8.28 | 3.31 % | $ 424 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.33 | 6.39 % | $ 46.8 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 1.07 | 3.88 % | $ 25 M | USA |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.17 | 3.4 % | $ 1.89 B | Canada |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.36 | 0.67 % | $ 1.08 B | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-42.3 M | $ 4.45 | 0.34 % | $ 287 M | USA |
 |
Perrigo Company plc
PRGO
|
238 M | $ 9.63 | -0.1 % | $ 1.33 B | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Tilray
TLRY
|
7.91 M | $ 6.99 | 4.95 % | $ 4.32 B | Canada |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.39 | 1.09 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.35 | 0.43 % | $ 2.92 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 6.57 | 7.7 % | $ 259 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.41 | 5.22 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.91 | 0.57 % | $ 45.4 M | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
-21.7 M | $ 2.33 | 1.75 % | $ 314 M | USA |
 |
Viatris
VTRS
|
2.9 B | $ 13.65 | 2.13 % | $ 16.4 B | USA |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 0.62 | 8.98 % | $ 10.8 M |  China |
 |
cbdMD
YCBD
|
-353 K | $ 0.79 | 0.86 % | $ 3.41 M | USA |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.47 | 2.49 % | $ 325 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.0 | 3.86 % | $ 108 M | Canada |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 17.53 | 6.18 % | $ 112 M | USA |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.4 | 4.8 % | $ 25.1 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Harrow Health
HROW
|
43.9 M | $ 35.82 | 1.76 % | $ 1.32 B | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |